Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Endometrial Cancer Excellence Forum

Endometrial Cancer
Learning Library
Leaders in the field sharing authoritative insights and institutional best practices.

Alessandro Santin, MD, Yale Cancer Center
Videos
Efficacy and Safety of Sacituzumab Govetican for Patients With Advanced Endometrial Cancer
09/05/2024
Alessandro Santin, MD, shares insights from the endometrial cancer cohort of the TROPiCS-03 trial, which evaluated sacituzumab govetican among patients with advanced endometrial cancer who have been heavily pretreated.
Alessandro Santin, MD, shares insights from the endometrial cancer cohort of the TROPiCS-03 trial, which evaluated sacituzumab govetican among patients with advanced endometrial cancer who have been heavily pretreated.
Alessandro Santin, MD, shares...
09/05/2024
Oncology
Kathleen Moore, MD, Stephenson Cancer Center
Videos
Treatment Landscape for Advanced/Recurrent Endometrial Cancer
08/26/2024
Kathleen Moore, MD, discusses the current treatment landscape for patients with advanced and recurrent endometrial cancer, considering the recent expanded indication of dostarlimab plus chemotherapy.
Kathleen Moore, MD, discusses the current treatment landscape for patients with advanced and recurrent endometrial cancer, considering the recent expanded indication of dostarlimab plus chemotherapy.
Kathleen Moore, MD, discusses...
08/26/2024
Oncology
BJ Rimel, MD, Cedars-Sinai Medical Center
Videos
Significance of Dostarlimab Plus Chemotherapy Approval for Primary Advanced or Recurrent Endometrial Cancer
08/23/2024
BJ Rimel, MD, shares insights on the recent FDA approval which expanded the previous indication for dostarlimab plus carboplatin-paclitaxel for all patients with primary advanced or recurrent endometrial cancer.
BJ Rimel, MD, shares insights on the recent FDA approval which expanded the previous indication for dostarlimab plus carboplatin-paclitaxel for all patients with primary advanced or recurrent endometrial cancer.
BJ Rimel, MD, shares insights on...
08/23/2024
Oncology
Matthew Powell, MD, Washington University School of Medicine in St Louis
Videos
Dostarlimab Plus Carboplatin And Paclitaxel for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/09/2024
Matthew Powell, MD, discusses the phase 3 RUBY trial, in which dostarlimab plus carboplatin-paclitaxel improved overall survival among patients with endometrial cancer, when compared with placebo plus carboplatin and paclitaxel.
Matthew Powell, MD, discusses the phase 3 RUBY trial, in which dostarlimab plus carboplatin-paclitaxel improved overall survival among patients with endometrial cancer, when compared with placebo plus carboplatin and paclitaxel.
Matthew Powell, MD, discusses...
08/09/2024
Oncology
Aine Clements, MD
Conference Coverage
Molecular Classification With Modified ProMisE Algorithm Predicts Survival Outcomes Among Patients With Endometrial Cancer
04/01/2024

Featuring Aine Clements, MD

Featuring Aine Clements, MD
Aine Clements, MD, discussed ancillary results from phase 3 GOG-0258 trial, as presented at the SGO 2024 Annual Meeting which demonstrated that molecular classification based on a modified ProMisE algorithm is prognostic in endometrial...
Aine Clements, MD, discussed ancillary results from phase 3 GOG-0258 trial, as presented at the SGO 2024 Annual Meeting which demonstrated that molecular classification based on a modified ProMisE algorithm is prognostic in endometrial...
Aine Clements, MD, discussed...
04/01/2024
Oncology
Bradley Corr, MD
Conference Coverage
Rucaparib Maintenance Therapy Improved Progression-Free Survival Among Patients With Recurrent or Metastatic Endometrial Cancer
03/21/2024

Featuring Bradley Corr, MD

Featuring Bradley Corr, MD
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting...
03/21/2024
Oncology
Joyce Barlin, MD, Women’s Cancer Care Associates, Albany, NY
Videos
Chemotherapy and Radiation Sandwich Therapy vs Standard of Care for Advanced Endometrial Cancer
04/05/2023
Joyce Barlin, MD, presents data from the Lunchbox trial at the SGO Annual Meeting on Women’s Cancer, comparing chemotherapy and radiation sandwich therapy vs chemotherapy alone for patients with advanced endometrial cancer.
Joyce Barlin, MD, presents data from the Lunchbox trial at the SGO Annual Meeting on Women’s Cancer, comparing chemotherapy and radiation sandwich therapy vs chemotherapy alone for patients with advanced endometrial cancer.
Joyce Barlin, MD, presents data...
04/05/2023
Oncology
Mansoor Raza Mirza, MD, Copenhagen University Hospital, Denmark
Conference Coverage
Beyond Immunotherapy Treatment for Patients With Recurrent Metastatic Endometrial Cancer
02/24/2023
At the 2023 ESMO Gynecological Cancers Congress, Mansoor Raza Mirza, MD, discusses the role of HER2, p53, and other molecular targets in treating patients with recurrent, metastatic endometrial cancer.
At the 2023 ESMO Gynecological Cancers Congress, Mansoor Raza Mirza, MD, discusses the role of HER2, p53, and other molecular targets in treating patients with recurrent, metastatic endometrial cancer.
At the 2023 ESMO Gynecological...
02/24/2023
Oncology

Advertisement

Recent Stories

Alessandro Santin, MD, Yale Cancer Center
Videos
Efficacy and Safety of Sacituzumab Govetican for Patients With Advanced Endometrial Cancer
09/05/2024
Alessandro Santin, MD, shares insights from the endometrial cancer cohort of the TROPiCS-03 trial, which evaluated sacituzumab govetican among patients with advanced endometrial cancer who have been heavily pretreated.
Alessandro Santin, MD, shares insights from the endometrial cancer cohort of the TROPiCS-03 trial, which evaluated sacituzumab govetican among patients with advanced endometrial cancer who have been heavily pretreated.
Alessandro Santin, MD, shares...
09/05/2024
Oncology
Kathleen Moore, MD, Stephenson Cancer Center
Videos
Treatment Landscape for Advanced/Recurrent Endometrial Cancer
08/26/2024
Kathleen Moore, MD, discusses the current treatment landscape for patients with advanced and recurrent endometrial cancer, considering the recent expanded indication of dostarlimab plus chemotherapy.
Kathleen Moore, MD, discusses the current treatment landscape for patients with advanced and recurrent endometrial cancer, considering the recent expanded indication of dostarlimab plus chemotherapy.
Kathleen Moore, MD, discusses...
08/26/2024
Oncology
BJ Rimel, MD, Cedars-Sinai Medical Center
Videos
Significance of Dostarlimab Plus Chemotherapy Approval for Primary Advanced or Recurrent Endometrial Cancer
08/23/2024
BJ Rimel, MD, shares insights on the recent FDA approval which expanded the previous indication for dostarlimab plus carboplatin-paclitaxel for all patients with primary advanced or recurrent endometrial cancer.
BJ Rimel, MD, shares insights on the recent FDA approval which expanded the previous indication for dostarlimab plus carboplatin-paclitaxel for all patients with primary advanced or recurrent endometrial cancer.
BJ Rimel, MD, shares insights on...
08/23/2024
Oncology
Matthew Powell, MD, Washington University School of Medicine in St Louis
Videos
Dostarlimab Plus Carboplatin And Paclitaxel for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/09/2024
Matthew Powell, MD, discusses the phase 3 RUBY trial, in which dostarlimab plus carboplatin-paclitaxel improved overall survival among patients with endometrial cancer, when compared with placebo plus carboplatin and paclitaxel.
Matthew Powell, MD, discusses the phase 3 RUBY trial, in which dostarlimab plus carboplatin-paclitaxel improved overall survival among patients with endometrial cancer, when compared with placebo plus carboplatin and paclitaxel.
Matthew Powell, MD, discusses...
08/09/2024
Oncology
Aine Clements, MD
Conference Coverage
Molecular Classification With Modified ProMisE Algorithm Predicts Survival Outcomes Among Patients With Endometrial Cancer
04/01/2024

Featuring Aine Clements, MD

Featuring Aine Clements, MD
Aine Clements, MD, discussed ancillary results from phase 3 GOG-0258 trial, as presented at the SGO 2024 Annual Meeting which demonstrated that molecular classification based on a modified ProMisE algorithm is prognostic in endometrial...
Aine Clements, MD, discussed ancillary results from phase 3 GOG-0258 trial, as presented at the SGO 2024 Annual Meeting which demonstrated that molecular classification based on a modified ProMisE algorithm is prognostic in endometrial...
Aine Clements, MD, discussed...
04/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement